D. Boral Capital restated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.
Tevogen Bio Price Performance
Shares of NASDAQ:TVGN opened at $1.07 on Tuesday. Tevogen Bio has a 12-month low of $0.26 and a 12-month high of $6.95. The business has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.17.
Insider Transactions at Tevogen Bio
In related news, insider Neal Flomenberg sold 70,384 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56. Following the transaction, the insider now owns 3,898,828 shares of the company’s stock, valued at $4,249,722.52. This trade represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 173,542 shares of company stock valued at $192,827. 56.60% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Tevogen Bio
Tevogen Bio Company Profile
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Featured Articles
- Five stocks we like better than Tevogen Bio
- The 3 Best Blue-Chip Stocks to Buy Now
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.